Clinical Trials Directory

If you join this study, you will first go through a screening period to make sure you qualify. If you qualify, you will be placed into one of two groups by chance, like drawing names from a hat. Group 1 will get one dose of a medicine called rademikibart. Group 2 will get one dose of a placebo, which looks like the medicine but does not have any active drug. The study will include about nine visits over a period of eight to thirty‑four weeks.

We are testing a new type of electrode and a special computer system that can read signals from the skin. The person in the study will wear these new electrodes on their feet.

We are doing this study to get more information about the safety and performance of the Signia® circular adapter and stapler (the study technology). This device is FDA-approved for use as a tool to connect or re-connect tissues after a surgery. We want to know how successful it is at promoting healing for people who have left sided colon, sigmoid, or rectal resections at Duke.

We are doing this study to find out if an investigational drug called RGN-259 Thymosin Beta 4 eye drops solution (the study drug) is a safe and effective option for the treatment of neurotrophic keratopathy.

We are doing this study to test the feasibility and acceptability of an experimental communication device. This device was invented by a team from the Duke Pratt School of Engineering and is intended to help people with dementia and their caregivers. We want to know if this tool can be used to help people with dementia who live at home with their families.

We are doing this study to find out if a study drug called ivosidenib is a safe and effective option for locally advanced or metastatic conventional chondrosarcoma with an isocitrate dehydrogenase 1 (IDH1) mutation.

In this study, people will take a medicine called S241656 by mouth. They may take it by itself or with other cancer treatments, and they may take it once or twice a day depending on their study group. The study has two parts. In Part 1, people receive different amounts of the medicine so researchers can find the safest dose. In Part 2, people receive the safest dose that was found in Part 1. Participants will keep taking the medicine until their cancer gets worse or the side effects become too strong or happen too often. During the study, they will visit the clinic regularly and have many tests, including blood tests, urine tests, and scans. The whole study is expected to last about five years.

We are doing this study to find out if an experimental drug combination made up of ivosidenib, gemcitabine, cisplatin, and durvalumab is a safe and effective for treating cholangiocarcinoma.